A phase 2 clinical trial of the diabetes drug pioglitazone in ALS was terminated after it failed to reach its primary endpoint of increased survival time

Posted on Tuesday, June 19, 2012 - 03:05, By: Other
The anti-diabetic drug pioglitazone did not improve survival time when tested as an add-on therapy to riluzole in a phase 2 clinical trial of people with amyotrophic lateral sclerosis (ALS). The trial, which was conducted in Germany, was stopped early "for futility" when interim results showed no...